Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on August 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 113,750 shares of common stock to 14 new employees.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Each stock option has an exercise price per share equal to $9.95, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option also has a ten year term and is subject to the terms and conditions of the Company's 2006 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Optimer in accordance with NASDAQ Listing Rule 5635(c)(4).

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a trea
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
2. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
3. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
6. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Expands Senior Management Team
8. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
9. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
10. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
11. Trading Halted Today in Optimer Pharmaceuticals Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PRINCETON, N.J. , March 5, 2015 ... late stage biopharmaceutical company committed to developing products that ... oncology and biodefense, announced today that its President and ... will give a corporate presentation at the 27 th ... California , on Tuesday, March 10, 2015 at ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Global Rising Stars Outlook 2015" report to ... diseases are being sought after with fresh vigor as ... field which is poised to bring a paradigm change ... decades is the Stem cell therapy/Regenerative Medicine space. ...
(Date:3/5/2015)... , March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, announced today that ... top rehabilitation hospitals for spinal cord injury and brain ... trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured ... injury (SCI). The Phase 1/2a trial ...
Breaking Medicine Technology:Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3Global Pharma Rising Stars Outlook 2015 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... the third quarter 2011 prior to the open of the ... H. Johnson, Chief Executive Officer and President, and Kenneth J. ... an investment community conference call beginning at 9:00 a.m. Eastern ...
... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... cell preservation company  focused on bringing the life saving ... today announced that its Board of Directors will conduct ... Cord Blood America to enhance shareholder value. ...
Cached Medicine Technology:Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011 2Cord Blood America, Inc. to Evaluate Possible Strategic Alternatives 2
(Date:3/5/2015)... At the 7th Annual Mississippi ... addiction treatment met today in Jackson, Mississippi to listen ... Among the numerous respected speakers will be William ... role that pain medications have had in today’s opiate ... , "It is hard to believe that much of ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... at Natural Products Expo West that its popular ready-to-drink ... percent soy and dairy free. Califia Farms Vegan Protein ... and are packed with six grams of an innovative ... fiber, B vitamins and magnesium. , Protein is an ...
(Date:3/5/2015)... 2015 University of Western States ... 1904, has launched a new center of excellence ... The Northwest Center for Lifestyle and Functional Medicine ... outreach, and conduct research in the areas of ... nutrition. The center will target efforts on the ...
(Date:3/5/2015)... 05, 2015 Supply & Demand Chain ... of “Pros to Know” in the supply chain industry, ... of MEBC’s leadership team were included on this year’s ... received this award due to their hard work, their ... for meeting and resolving client needs and challenges. ...
(Date:3/5/2015)... Dr. Jonathan Glashow a board certified New ... named by Castle Connolly as a Top ... has been selected by Castle Connolly Medical Ltd. for ... care doctors in the tri-state metropolitan New York area ... carefully screens and selects doctors through a rigorous peer ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... , , , ... month that the first recipients enrolled in Medicare. Now is the time ... for all," said Dr. Jane L. Delgado, President and CEO of the National ... , , "President Obama set out in his ...
... Evidence That Criticisms Are Registering As Debate Intensifies , ... Congress works through specific health reform proposals, the July Kaiser Health Tracking Poll ... reform now, though there is some softening of support as criticisms and doubts ... been the case over the past ten months, a majority of the American ...
... 28th Annual KLOS Blood Drive Aims ... LOS ANGELES, July 22 The American Red Cross and 95.5 KLOS ... Blood Drive. The 2009 KLOS Blood Drive will run for five days, ... and classic rock fans are encouraged to donate at any of the 19 ...
... , INCLINE VILLAGE, Nev., July 22 PDL BioPharma, ... hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. ... and provide a business update. The call and webcast will follow the release ... , , Conference Call Details , ...
... shows devices contain carcinogens, other toxins , WEDNESDAY, ... cigarettes, known as e-cigarettes, has shown that they ... compound used in antifreeze, U.S. health officials said ... cartridges filled with nicotine, flavorings and other chemicals. ...
... WASHINGTON, July 22 There are many provisions in ... care greatly about the freedom to choose their health care. Some of ... * Eliminates Existing Private Insurance Coverage (i.e., Eliminates Your Choice ... But Is Just Fine With You and Your Family) , ...
Cached Medicine News:Health News:Time to Get the Job Done Says Alliance President and CEO 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 2Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 3Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 4Health News:Majority of Public Maintains Support for Addressing Health Care Reform Now 5Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 2Health News:KLOS & Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 3Health News:PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 2Health News:E-Cigarettes Pose a Health Hazard, FDA Warns 3Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2
... The Benchtop Fume Hood is an economical ... in which a number of fume hoods ... junior colleges and universities. Features include a ... with rounded inside corners for easy cleaning. ...
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
... most convenient for sectioning of specimens in ... Specimen rise is automatic and accurate with ... microns in increments of 0.5 microns. ... Products, Vibratomes Freezing Stages ...
... MNL 440601 Small Sledge Microtome is ideal for ... or skin specimens. Specimen rise is automatic ... 30 microns in increments of 2 microns. ... Stages.,Other Associated Products, Vibratomes Freezing Stages ...
Medicine Products: